Climb Bio (CLYM) Receivables - Accured (2021 - 2025)

Climb Bio (CLYM) has 5 years of Receivables - Accured data on file, last reported at $1.4 million in Q1 2025.

• Quarterly Receivables - Accured changed N/A year-over-year to $1.4 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.4 million (changed N/A YoY) and the FY2024 annual result came in at $1.1 million, up 154.32% from the prior year.
• Receivables - Accured rose to $1.4 million in Q1 2025, from $1.1 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $1.4 million in Q1 2025 to a low of $100000.0 in Q4 2022.
• A 5-year average of $467307.7 and a median of $300000.0 in 2021 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2022 — Receivables - Accured slumped 80.0% — and 2023, when it jumped 300.0%.
• Tracing CLYM's Receivables - Accured over 5 years: stood at $500000.0 in 2021, then tumbled by 80.0% to $100000.0 in 2022, then jumped by 300.0% to $400000.0 in 2023, then soared by 179.75% to $1.1 million in 2024, then rose by 22.07% to $1.4 million in 2025.
• The last three Receivables - Accured figures came in at $1.4 million (Q1 2025), $1.1 million (Q4 2024), and $990000.0 (Q3 2024), per Business Quant data.